Study of the CD40 Agonistic Monoclonal Antibody APX005M
Status:
Completed
Trial end date:
2018-06-19
Target enrollment:
Participant gender:
Summary
This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal
antibody APX005M in adults with solid tumors. Study is intended to establish the maximum
tolerated dose and the overall safety and tolerability of APX005M in 3 different
administration schedules.